Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning
Status:
Recruiting
Trial end date:
2022-11-30
Target enrollment:
Participant gender:
Summary
Various approaches are currently being developed for prostate cancer immunotherapy. However,
a major challenge facing the development of cancer immunotherapy is the identification of
tumors that would best respond to this type of treatment. Different studies suggest that
prostate cancer more likely to progress are more infiltrated by exhausted T cells expressing
the cell surface protein PD1 (Programmed cell death 1). Therefore, there is a strong
rationale for selecting patients at higher risk of progression for testing the efficacy of
anti-PD1 therapy.
High glucose metabolism as detected by fludeoxyglucose F18 (FDG)-positron emission tomography
(PET) (18FDG-PET) imagery is an innovative biological biomarker-based method to identify
patients at higher risk of recurrence and early failure to hormonotherapy. Recent study
demonstrated that high intra-prostatic 18-FDG-uptake was associated with higher Gleason
grades. Therefore the one third of Gleason ≥ 8 prostate cancer patients with higher 18FDG
uptake would be ideal candidates for early immunotherapy treatments based on anti-PD-1 such
as pembrolizumab.
The study aimed to identify biomarkers predictive the response to Pembrolizumab given prior
to radical prostatectomy in participants with primary prostate cancer at high risk of
progression.